Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(5 months from now) | |
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | May 2, 2022 |
New Indication (I) | May 2, 2022 |
Market Authorisation Date: 27 February, 2017
Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic